ELI LILLY & Co (LLY) — Fundamental Analysis

Eli Lilly & Co is in the middle of one of the most dramatic growth runs in large-cap pharma history, driven almost entirely by its blockbuster GLP-1 drugs Mounjaro and Zepbound. Revenue has nearly tripled over the past three years — from roughly $28.5 billion in 2022 to $65.2 billion in 2025 — and net profit margins are expanding sharply, hitting nearly 32% in fiscal 2025 and accelerating further into early 2026. The balance sheet carries meaningful debt (debt-to-equity around 1.4x as of the most recent quarter), but liquidity has improved noticeably, and capital expenditures remain modest relative to revenue, suggesting the business is still generating cash well in excess of what it needs to reinvest. In short: Lilly is growing fast, becoming more profitable, and looks financially healthier than it did two years ago — the key question for investors is whether that growth rate can be sustained as competition in the GLP-1 space intensifies.

Snapshot & Big Picture

Eli Lilly, headquartered in Indianapolis, Indiana, is one of the world's largest pharmaceutical companies. Over the past decade it has transformed from a steady mid-sized pharma player into a revenue juggernaut, largely on the back of its diabetes and obesity drug portfolio. The 10-year revenue CAGR of ~12.6% understates how steep the recent acceleration has been — the 3-year CAGR clears 31.7%, reflecting the explosive commercial ramp of tirzepatide (Mounjaro/Zepbound). Fiscal year 2025 revenue of $65.2 billion represents a 45% jump over fiscal 2024's $45.0 billion, itself a 32% jump over 2023. This is not incremental growth; it is a step-change in scale.

Latest Quarter Snapshot

The most recent data point — Q1 2026 (period ending March 31, 2026, filed April 30, 2026) — is more current than the annual figures and paints an even more favorable picture. Quarterly revenue came in at $19.8 billion, which annualizes to nearly $79 billion if sustained. Net margin for the quarter reached 37.4%, the highest reading in the dataset and a meaningful step up from the already-strong full-year 2025 figure of 31.7%. The current ratio improved to 1.50, and debt-to-equity fell further to 1.39, continuing the deleveraging trend visible since the 2023–2024 peak. Capital expenditures for Q1 2026 were $365.4 million, representing a capex-to-revenue ratio of approximately 1.85% — a relatively modest reinvestment burden for a company of Lilly's scale, suggesting strong free cash flow generation.

Profitability

Lilly's net margin history is anything but linear. The company posted a small net loss in 2017 (-1.0%), likely reflecting one-time charges or tax items, before rebounding to a brief spike in 2019 (37.3%) — a year in which debt-to-equity also spiked to nearly 5.9x, suggesting that year's margin may have been distorted by asset sales or non-recurring items. Stripping out those anomalies, the underlying trend from 2020 onward is clearly upward: margins of 25%, then 20%, dipped to 15% in 2023 (likely reflecting heavy R&D and commercialization spend for the GLP-1 launch), then rebounded sharply to 23.5% in 2024 and 31.7% in 2025. The Q1 2026 reading of 37.4% suggests operating leverage is kicking in at scale — as manufacturing capacity catches up to demand and the revenue base grows, fixed costs are being spread over an increasingly large top line. EBITDA and gross/operating margin data were not available in the filings provided, so a more granular profitability breakdown cannot be presented here.

Financial Health

Lilly's balance sheet has gone through notable cycles. Debt-to-equity was low through 2016 (0.55–0.74x), rose sharply in 2019–2020 as the company borrowed to fund its pipeline buildout, then moderated to the 1.5–2.4x range from 2021 onward. The peak of 2.36x in 2024 has already come down to 1.60x by end of 2025 and 1.39x in Q1 2026 — a meaningful improvement driven by strong earnings growth expanding the equity base. Current ratio dipped below 1.0x briefly in 2023 (0.94x), signaling a moment of tighter short-term liquidity, but has since recovered to 1.58x (FY2025) and 1.50x (Q1 2026), both comfortable readings.

On capital expenditures: the annual 10-K filings did not include a capex figure in the data provided, so a multi-year capex trend cannot be constructed from the annual dataset. What is available is the Q1 2026 quarterly figure of $365.4 million, or about 1.85% of that quarter's revenue. This is a relatively low capital intensity ratio, consistent with what one would expect from a pharmaceutical business whose primary value drivers are intellectual property and clinical outcomes rather than heavy physical infrastructure. That said, Lilly has publicly announced substantial manufacturing investments to address GLP-1 supply constraints, so capex-to-revenue may rise in coming periods as those facilities are built out. Investors should watch this metric in future quarterly filings.

Growth

The CAGR table tells a compelling story of acceleration: over the past decade Lilly grew at a respectable but unremarkable 12.6% annually, but zoom into the most recent three years and that figure more than doubles to 31.7%. The convergence of Mounjaro and Zepbound achieving commercial scale is entirely responsible for this inflection — and the Q1 2026 revenue run-rate suggests the acceleration has not yet plateaued. The 5-year CAGR of 21.6% sits neatly between the two extremes, reflecting that the GLP-1 tailwind really began building around 2022–2023. Whether the 3-year CAGR can be sustained is the central investment question; consensus expectations for GLP-1 market growth remain very strong, but supply, competition, and pricing pressure from the Inflation Reduction Act negotiations are real variables to monitor.

Source Filings

• 10-Q — Filed April 30, 2026 (Period ending March 31, 2026)
• 10-K — Filed February 12, 2026 (Fiscal Year ending December 31, 2025)